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Immunomodulating agents (ImiDs) are a novel class of anti-1
cancer drugs that have demonstrated impressive antitumor
activity in various malignant disorders. Of this class, most
recent research has been focused on the remarkably active
agent, lenalidomide. Lenalidomide was designed to enhance
immunologic and anticancer properties while potentially
decreasing neurotoxic and teratogenic adverse eﬀects of
the parent compound thalidomide. The introduction of
this novel agent has broadened the therapeutic landscape
of hematologic malignant disorders including multiple
myeloma (MM) and, more recently, other B-cell neoplasms.
In this issue, we focused on mechanisms of action and
results from clinical investigation that report the relevance of
lenalidomide for the treatment of B-cell disorders including
MM, chronic lymphocytic leukaemia (CLL), and non-
Hodgkin’s lymphomas by oﬀering new mechanisms for
targeting these diseases. In particular, papers defining the
role of lenalidomide as part of the induction therapy before
hematopoietic stem cells transplantation (HSCT) as well
as its use as extended maintenance therapy post-HSTC in
patients with MM will be of great interest.
In this special issue, we invited papers on potential topics
including, but are not limited to, lenalidomide: mechanism
of action, lenalidomide as part of the induction therapy
before HSCT and its use as consolidation and maintenance
therapy of multiple myeloma, lenalidomide in chronic
lymphocytic leukaemia, lenalidomide in diﬀuse large B-cell
lymphoma, and lenalidomide in mantle cell and low-grade
non-Hodgkin’s lymphomas. Ten articles discuss the role of
lenalidomide in the treatment of malignant disorders.
The paper entitled “Lenalidomide in diﬀuse large B-cell
lymphoma” by C. Thieblemont et al. presents the biological
rational for the use of lenalidomide in DLBCL in light of
recent advances in the pathophysiology of the disease and
the therapeutic results of the most recent trials published
in literature or reported in meetings in relapsed/refractory
situations as well as in first-line treatment. The paper entitled
“Practical approaches to the use of lenalidomide in multiple
myeloma: a Canadian consensus” by D. Reece et al. discuss
the use of lenalidomide in the management of RRMM in
the Canadian environment. The Chair (DR) invited panelists
to research and write individual sections of the paper. The
various sections were collected, compiled, and distributed to
the group, which discussed the paper via web conference.
Panelists subsequently generated a revised draft in which
all sections included specific clinical guidance (i.e., practice
considerations). The revised paper was discussed at a final
web conference, where all practice recommendations were
considered, revised as appropriate, and ultimately adopted
by the full panel; any areas of disagreement are noted.
Celgene Canada provided the impetus for the panel to
pursue this project freely and independently. Celgene Canada
supported the process throughout, including support for
the participation of a medical writer (JA) in preparing this
paper. The opinions represented here are solely those of the
physician-panelists.
The paper entitled “Biological activity of lenalidomide
and its underlying therapeutic eﬀects in multiple myeloma”
by R. Martiniani et al. is about the direct and indirect
antitumor eﬀects of lenalidomide on malignant plasmacells,
bone marrow microenvironment, bone resorption, and
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host’s immune response. The molecular mechanisms and
targets of lenalidomide remain largely unknown, but recent
evidence shows cereblon (CRBN) as a possible mediator of
its therapeutical eﬀects.
The paper entitled “Molecular action of lenalidomide
in lymphocytes and hematologic malignancies” by J. M.
McDaniel et al. summarizes the current information about
lenalidomide in proliferative neoplasms and describes our
understanding of the molecular mechanism of action in lym-
phocytes. Based on the overwhelming success of lenalido-
mide for the treatment of several hematologic malignancies,
there is potential for therapies that augment host immune
responses to be extended from the relapsed and refractory
setting, to primary therapy.
The paper entitled “Secondary primary malignancies in
multiple myeloma: an old nemesis revisited” by J. Yang et
al. reviews the developmental history of myeloma therapy,
with particular emphasis on the risk of secondary cancers,
and examine the available data with regard to the risk
of SPMs seen with lenalidomide. We also speculate about
the mechanism(s) by which lenalidomide could increase
the risk of second cancers. To conclude, we make some
recommendations about how our current understanding
aﬀects our treatment decisions and suggest directions for
future research. As new data emerge about lenalidomide and
the risk of SPMs, it is our hope that this paper will help to
put that information in proper perspective.
The paper entitled “Lenalidomide in the treatment of
young patients with multiple myeloma: from induction to
consolidation/maintenance therapy” by B. Lupo et al. presents
an overview of the results achieved with lenalidomide-
containing combinations in patients eligible for high-dose
therapies, namely, young patients. The advantages obtained
should always be outweighed with the toxicity profile asso-
ciated with the regimen used. Therefore, here, we will also
provide a description of the main adverse events associated
with lenalidomide and its combination.
The paper entitled “Lenalidomide in the treatment of
chronic lymphocytic leukemia” by A. Cortelezzi et al. provides
a comprehensive summary regarding mechanism of action,
eﬃcacy, and safety of lenalidomide in CLL patients. Relevant
clinical trials using lenalidomide alone or in combination
are discussed. Lenalidomide shows good activity also in
relapsed/refractory or treatment-naive CLL patients. Defini-
tive data from ongoing studies are needed to validate overall
and progression-free survival. The toxicity profile might
limit lenalidomide use because it can result in serious side
eﬀects, but largely controlled by gradual dose escalation.
Further understanding of the exact mechanism of action in
CLL will allow more eﬃcacious use of lenalidomide alone or
in combination regimens.
The paper entitled “Lenalidomide in diﬀuse large B-
cell lymphomas” by A. Chiappella et al. reports the most
relevant clinical trials for the use of lenalidomide in DLBCL.
Monotherapy with lenalidomide showed an activity in terms
of overall response rate, with acceptable hematological and
extrahematological toxicities in relapsed/refractory aggres-
sive NHL. The role of lenalidomide as salvage therapy in
both cell of origin patterns in DLBCL (germinal center
B cell/activated B cell) was reported in preliminary data.
Preliminary data regarding the role of lenalidomide in
addition to chemoimmunotherapy (R-CHOP) in first-line
clinical trials were discussed; data of safety, feasibility, and
eﬃcacy were promising.
The paper entitled “Therapeutic activity of lenalido-
mide in mantle cell lymphoma and indolent non-Hodgkin’s
lymphomas” by M. Gunnellini et al. discusses the role of
lenalidomide in the therapeutic armamentarium of patients
with indolent NHL or MCL.
The tenth paper entitled “Lenalidomide before and after
autologous hematopoietic stem cell transplantation in multiple
myeloma” by S. A. Tuchman et al. summarizes existing data
that pertains to lenalidomide in the specific context of ASCT,
and we share our thoughts on how our own group applies
these data to approach this complex issue clinically.
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